Catalpol Enhances Neurovascular Repair in Ischemic Stroke Models

Study Background and Research Question

The neurovascular unit (NVU), encompassing neurons, astrocytes, and vascular endothelial cells, is fundamental for maintaining brain homeostasis and blood–brain barrier (BBB) integrity. Disruption of this multicellular network is central to the pathogenesis of ischemic stroke, leading to loss of neuronal function, impaired vascular integrity, and compromised neuroprotection. Despite advances in acute stroke management, repairing NVU dysfunction remains a major challenge, and pharmacological strategies targeting holistic NVU restoration are of significant interest. Catalpol, an iridoid glycoside derived from Rehmannia glutinosa, has shown neuroprotective effects in several preclinical models, but its mechanism of action in the context of the NVU after ischemic injury was not fully defined. The recent reference study addresses whether Catalpol can ameliorate NVU impairment in ischemic stroke, and through which molecular pathways.

Key Innovation from the Reference Study

The central innovation of the reference study is the demonstration that Catalpol exerts multi-faceted protective effects on the NVU in a rat model of ischemic stroke, primarily via upregulation of VEGF and activation of PI3K/AKT and MEK1/2/ERK1/2 signaling. Unlike prior work focusing on neuronal or vascular endpoints in isolation, this study integrates structural and molecular analyses to show how Catalpol preserves vessel-neuron-astrocyte architecture, stimulates angiogenesis and neurogenesis, and activates a feed-forward signaling loop crucial for NVU repair. This positions Catalpol as a model compound for dissecting holistic NVU protection in translational stroke research.

Methods and Experimental Design Insights

The researchers utilized the permanent middle cerebral artery occlusion (MCAO) rat model, a standard paradigm for studying ischemic stroke pathophysiology and intervention. Catalpol was administered intravenously at doses of 2.5, 5.0, and 10.0 mg/kg/day for 14 days post-stroke onset. The study evaluated infarction volume, neurological deficit scores, and NVU integrity through histological and immunofluorescence analyses. Molecular endpoints included expression levels of vascular endothelial growth factor (VEGF), phosphorylated PI3K/AKT, FAK, Paxillin, and MEK1/2/ERK1/2 components in peri-infarct regions. To strengthen translatability, a three-dimensional in vitro NVU model subjected to oxygen-glucose deprivation (OGD) was also employed to probe Catalpol’s protective mechanisms in a controlled cellular environment.

Core Findings and Why They Matter

1. Dose-dependent NVU Protection and Functional Recovery: Catalpol treatment reduced infarct size and improved neurological scores in MCAO rats in a dose-dependent manner, with 10 mg/kg/day showing the most pronounced effects (reference study).

2. Preservation of NVU Architecture: Histological analyses revealed that Catalpol preserved vessel-neuron-astrocyte structures in the peri-infarct cortex, mitigating disorganization and cell loss typical of ischemic injury. This included maintenance of tight junction proteins, astrocytic end-feet, and microvascular density, all essential for BBB function and neural support.

3. Promotion of Angiogenesis and Neurogenesis: Catalpol enhanced markers of both angiogenesis (CD31, VEGF) and neurogenesis (DCX, BrdU incorporation), supporting the notion that NVU repair requires coordinated vascular and neuronal regeneration.

4. Mechanistic Insights—VEGF-PI3K/AKT and MEK1/2/ERK1/2 Activation: Molecular assays confirmed that Catalpol upregulated VEGF expression and stimulated phosphorylation of PI3K/AKT and MEK1/2/ERK1/2 pathway components. Notably, VEGF signaling appeared to amplify both PI3K/AKT and MEK1/2/ERK1/2 activation, suggesting a feed-forward mechanism for sustaining NVU protection. These pathways are recognized as central to cell survival, migration, and differentiation in the context of injury recovery.

5. In Vitro Validation: In the 3D NVU OGD model, Catalpol similarly preserved cell viability and structural integrity via VEGF-dependent signaling, underscoring the compound’s direct action on NVU cells in addition to possible systemic effects.

The significance of these findings is twofold: they mechanistically validate Catalpol as a multi-pathway NVU-protective agent and provide a rationale for its use in translational models of ischemic stroke and other neurodegenerative conditions characterized by NVU impairment.

Comparison with Existing Internal Articles

The present findings build upon broader themes in liver fibrosis research, where Catalpol’s multi-pathway actions, including NF-κB and SIRT1/HIF-1α modulation, have been leveraged for anti-fibrotic and neuroprotection research. In the context of translational disease modeling, Catalpol’s role as a validated modulator of PI3K/AKT and ERK1/2 signaling is highlighted across models—including osteoporosis animal models and ischemic stroke. While the current reference paper focuses specifically on VEGF-mediated NVU protection post-stroke, the mechanistic overlap with pathways described in these internal resources reinforces Catalpol’s relevance as a tool compound for multi-domain disease modeling.

Further, the technical guidance resource for Catalpol provides detailed workflow and protocol suggestions for its use in diverse disease models, aligning with the dosing, administration, and mechanistic endpoints reported in the reference study. The integration of these resources supports reproducibility and cross-model insights for researchers employing Catalpol in NVU, liver, and bone disease contexts.

Limitations and Transferability

Several limitations of the reference study should be considered. First, while the MCAO rat model recapitulates key aspects of human ischemic stroke, species-specific differences and the artificial nature of permanent occlusion may limit direct translational extrapolation. The 14-day post-stroke administration window reflects a subacute intervention, and further studies are warranted to assess chronic and delayed treatment paradigms. Additionally, although the study robustly links VEGF-PI3K/AKT and MEK1/2/ERK1/2 signaling to NVU protection, it does not exclude contributions from other pathways previously implicated in Catalpol’s actions (e.g., NLRP3 inflammasome, TrkB-BDNF). Cross-model validation—such as in comorbid or aged animal cohorts—remains an open area for future investigation.

Transferability to other disease models, such as neurodegenerative disorders or liver fibrosis, is plausible given the shared reliance on PI3K/AKT and ERK1/2 signaling for tissue repair and cell survival. However, as emphasized in internal protocol resources, each model requires tailored dosing, administration, and endpoint selection to ensure scientific rigor and reproducibility.

Protocol Parameters

• MCAO dosing: 2.5–10 mg/kg/day, intravenous injection, for 14 consecutive days post-occlusion; 10 mg/kg/day provided maximal NVU protection in the reference study.
• In vitro NVU model: Catalpol concentrations ranging from 2 to 100 μM, with 24-hour pre-OGD treatment showing protective effects on NVU-like cultures.
• Endpoints: Infarct volume, neurological deficit scoring, immunohistochemistry for NVU markers (VEGF, CD31, DCX), and Western blot for PI3K/AKT and MEK1/2/ERK1/2 activation.
• Workflow tip: For optimal solubility and reproducibility, dissolve Catalpol at ≥25.25 mg/mL in water or ≥22.7 mg/mL in DMSO, and store aliquots at -20°C to avoid compound degradation, per product information.

Research Support Resources

Researchers interested in modeling neurovascular protection or replicating these results can obtain high-purity Catalpol (SKU N1352) from APExBIO. For practical handling, dosing, and troubleshooting guidance in diverse neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis models, refer to the linked protocol and review resources above. Catalpinoside and related glycosides remain underexplored for comparative NVU research, presenting additional avenues for mechanistic studies.